RT Journal Article
SR Electronic
T1 A Genomic Survey of SARS-CoV-2 Reveals Multiple Introductions into Northern California without a Predominant Lineage
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.27.20044925
DO 10.1101/2020.03.27.20044925
A1 Deng, Xianding
A1 Gu, Wei
A1 Federman, Scot
A1 Plessis, Louis du
A1 Pybus, Oliver G.
A1 Faria, Nuno
A1 Wang, Candace
A1 Yu, Guixia
A1 Pan, Chao-Yang
A1 Guevara, Hugo
A1 Sotomayor-Gonzalez, Alicia
A1 Zorn, Kelsey
A1 Gopez, Allan
A1 Servellita, Venice
A1 Hsu, Elaine
A1 Miller, Steve
A1 Bedford, Trevor
A1 Greninger, Alexander L.
A1 Roychoudhury, Pavitra
A1 Starita, Lea M.
A1 Famulare, Michael
A1 Chu, Helen Y.
A1 Shendure, Jay
A1 Jerome, Keith R.
A1 Anderson, Catie
A1 Gangavarapu, Karthik
A1 Zeller, Mark
A1 Spencer, Emily
A1 Andersen, Kristian G.
A1 MacCannell, Duncan
A1 Paden, Clinton R.
A1 Li, Yan
A1 Zhang, Jing
A1 Tong, Suxiang
A1 Armstrong, Gregory
A1 Morrow, Scott
A1 Willis, Matthew
A1 Matyas, Bela T.
A1 Mase, Sundari
A1 Kasirye, Olivia
A1 Park, Maggie
A1 Chan, Curtis
A1 Yu, Alexander T.
A1 Chai, Shua J.
A1 Villarino, Elsa
A1 Bonin, Brandon
A1 Wadford, Debra A.
A1 Chiu, Charles Y.
YR 2020
UL http://medrxiv.org/content/early/2020/03/30/2020.03.27.20044925.abstract
AB The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has spread globally, resulting in >300,000 reported cases worldwide as of March 21st, 2020. Here we investigate the genetic diversity and genomic epidemiology of SARS-CoV-2 in Northern California using samples from returning travelers, cruise ship passengers, and cases of community transmission with unclear infection sources. Virus genomes were sampled from 29 patients diagnosed with COVID-19 infection from Feb 3rd through Mar 15th. Phylogenetic analyses revealed at least 8 different SARS-CoV-2 lineages, suggesting multiple independent introductions of the virus into the state. Virus genomes from passengers on two consecutive excursions of the Grand Princess cruise ship clustered with those from an established epidemic in Washington State, including the WA1 genome representing the first reported case in the United States on January 19th. We also detected evidence for presumptive transmission of SARS-CoV-2 lineages from one community to another. These findings suggest that cryptic transmission of SARS-CoV-2 in Northern California to date is characterized by multiple transmission chains that originate via distinct introductions from international and interstate travel, rather than widespread community transmission of a single predominant lineage. Rapid testing and contact tracing, social distancing, and travel restrictions are measures that will help to slow SARS-CoV-2 spread in California and other regions of the USA.Competing Interest StatementCYC is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC) and receives research support funding from Abbott Laboratories. CYC and XD are inventors on a patent application on the MSSPE method titled “Spiked Primer Design for Targeted Enrichment of Metagenomic Libraries” (US Application No. 62/667,344, filed 05/04/2018 by University of California, San Francisco). HYC is a consultant for Merck and GlaxoSmithKline, and receives research funding from Sanofi-Pasteur, Ellume and Cepheid, unrelated to this work. All other authors have no conflicts to declare. The opinions expressed by the authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated. Funding StatementThis work was funded by NIH grants R33-AI129455 (CYC) from the National Institute of Allergy and Infectious Diseases, the Charles and Helen Schwab Foundation (CYC), K08-CA230156 (WG), and the Burroughs-Wellcome CAMS Award (WG).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe assembled SARS-CoV-2 genomes in this study were uploaded to GISAID (28-29) as FASTA files, and can be visualized on a continually updated phylogenetic tree on NextStrain (30). Submission of the genomes and raw sequence data to NIH GenBank and Sequence Read Archive (SRA) is pending https://www.gisaid.org/epiflu-applications/next-hcov-19-app/